A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from a Phase 2 study. The results bring hope to these difficult-to-treat patients whose disease continues to progress despite taking available therapies and have exhausted approved…
Researchers say they have developed a low-cost, reliable, chip-based blood test to detect multiple myeloma, which could replace the painful bone marrow biopsy. Their study, “Isolation of Circulating Plasma Cells from Blood of Patients Diagnosed with Clonal Plasma Cell Disorders using Cell Selection Microfluidics,” was published…
A collaboration between GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) resulted in the discovery of a biomarker called CHEK1 that detects which myeloma patients might benefit from a stem cell transplant. The finding was recently revealed at the 59th American Society of Hematology (ASH) Annual Meeting…
An Adaptimmune therapy that strengthens immune T-cells’ response to cancer has helped patients with advanced myeloma live as long as five years without their disease progressing, long-term results of a Phase 1/2a clinical trial show. Another important finding was that the 25 patients, all of whom had received stem cell transplants,…
Get regular updates to your inbox.